Childhood multiple sclerosis: course and management

References

• Duquette P, Murray TJ, Pleines J, Ebers GC. Multiple sclerosis in childhood: clinical profile in 125 patients. J. Pediatr. 111,359-363 (1987).
   Google Scholar
• •Although it belongs to the preMRI era and not all cases diagnosed by the authors, this is the largest series of childhood MS published to date.
   Google Scholar
• Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. NeuroL 13,227–231(1983).
   PubMed Web of Science ®Google Scholar
• ••Reference article on the diagnosis of MSfor research purposes.
   Google Scholar
• McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis Ann. NeuroL 50, 121–127 (2001).
   Web of Science ®Google Scholar
• ••Reference article on diagnostic criteria.
   Google Scholar
• Hanefeld FA, Bauer HJ, Christen HJ, Kruse B, Bruhn H, Frahm J. Multiple sclerosis in childhood: report of 15 cases. Brain Dev. 13,410–416 (1991).
   PubMed Web of Science ®Google Scholar
• Selcen D, Anlar B, Renda Y. Multiple sclerosis in childhood: report of 16 cases. Eur. NeuroL 36,79–84 (1996).
   Google Scholar
• Cole GE Stuart CA. A long perspective on childhood multiple sclerosis. Dev. Med. Child NeuroL 37, 661–666 (1995).
   Google Scholar
• Balassy CS, Bernert G, WOber-Bingöl C et al. Long-term MRI observations of childhood-onset relapsing-remitting multiple sclerosis Neuropediatrics32,28–37 (2000).
   Google Scholar
• Ruggieri M, Polizzi A, Pavone L, Grimaldi LME. Multiple sclerosis in children under 6 years of age. Neurology53,478–484 (1999).
   PubMed Web of Science ®Google Scholar
• •Review of the literature containing 49 cases, including six of the authors' own: the largest series in this age-group.
   Google Scholar
• Sindern E, Haas J, Stark E, Wurster U. Early onset MS under the age of 16; clinical and paraclinical features. Ada NeuroL Scand 86,280–284 (1992).
   PubMed Web of Science ®Google Scholar
• Pinhas-Harniel 0, Barak Y, Siev-Ner I, Achiron A. Juvenile multiple sclerosis: clinical features and prognostic characteristics. J. Pedian: 132,735-737 (1998).
   Google Scholar
• Bo iko AN, Gusova ME, Guseva MR et a/. Clinico-immunologic characteristics of multiple sclerosis with optic neuritis in children. J. NeuroviroL 6, S152–155 (2000).
   Google Scholar
• Hanefeld FA. Characteristics of childhood multiple sclerosis. bit. MSJ 1,91–97 (1997).
   Google Scholar
• Kurtzke JF. Further notes on disability evaluation in multiple sclerosis, with scale modifications. Neurology15, 654–661 (1965).
   PubMed Web of Science ®Google Scholar
• ••Reference article on the most frequentlyused disability scale for MS.
   Google Scholar
• Hynson JL, Kornberg AJ, Coleman LT et al. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology56, 1308–1312 (2001).
   PubMed Web of Science ®Google Scholar
• Dale RC, de Sousa C, Chong WK, Cox TC, Harding B, Neville BG. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 123 (Pt 12), 2407–2422 (2000).
   PubMed Web of Science ®Google Scholar
• •Extensive evaluation of patient series for features helpful in the differential diagnosis of these entities.
   Google Scholar
• Heesen C, Hauer S, Hadji-Abdolrahim B, Berenbeck C, Buhmann C, Emskotter T. Current status of multiple sclerosis therapy in Germany: a national survey. Eur. NeuroL 6(1), 35–38 (1999).
   Google Scholar
• Tremlett HL, Luscombe DK, Wiles CM. Prescribing for multiple sclerosis patients in general practice: a case-control study. J. Clin. Pharm. Ther. 26,437-444 (2001).
   Google Scholar
• Rudick RA, Fisher E, Lee JC, Duda JT, Simon J. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS and treatment with interferon beta-la. Mult. Scler. 6(6), 365–372 (2000).
   Google Scholar
• Beck RW, Cleary PA, Trobe J et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl. J. Med. 329, 1764–1769 (1993).
   PubMed Web of Science ®Google Scholar
• Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Neurology49, 1404–1413 (1997).
   Google Scholar
• Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weishenker BG. Plasma exchange for severe attacks of CNS demyelination: Predictors of response. Neurology58, 143–146 (2002).
   PubMed Web of Science ®Google Scholar
• Goodin DS, Frohman EM, Germany GP et al. Disease modifying therapies in multiple sclerosis. Neurology 58, 169–178 (2002).
   PubMed Web of Science ®Google Scholar
• ••Review of available data and summaryrecommendations on interferons and other immunomodulating treatment methods in MS.
   Google Scholar
• Polman CH, Uitdehaag BMJ. Drug treatment of multiple sclerosis. Br. Med. J. 321,490-494o:00y
   Google Scholar
• The IFN-B Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon-beta lb in the treatment of multiple sclerosis. Final outcome of the randomized controlled trial. Neurology45,1277–1285 (1995).
   Google Scholar
• Allain H, Schack S. Observation on differences between interferons used to treat multiple sclerosis. J. Clin. Res. 1,381–392 (1998).
   Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon beta-la for disease progression in exacerbating-remitting mutiple scerosis. Ann. NeuroL 39,285–294 (1996).
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA et al. Extended use of glatiramer acetate (Copaxone) is well-tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology50,701–708 (1998).
   PubMed Web of Science ®Google Scholar
• Sela M, Teitelbaum D. Glatiramer acetate in the treatment of multiple sclerosis. Expert Opin. Pharmacother. 2(7), 1149–1165 (2001).
   Google Scholar
• Francis DA. Glatiramer acetate (Copaxone). Int. Clin. Pract. 55 (6), 394–398 (2001).
   Google Scholar
• Warrington AE, Bieber AJ, Bogoljub C et al. Immunoglobulin-mediated CNS repair. j Allergy Clin. Immunol. 108, S121–125 (2001).
   PubMed Web of Science ®Google Scholar
• •Presents data on the effect of Igs on remyelination and discusses its possible mechanisms.
   Google Scholar
• Kolar O J, Finley JC. Effects of iv. methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurology51, 1516 (1998).
   Google Scholar
• Yudkin PL, Ellison GW, Ghezzi A etal. Overview of azathioprine treatment in multiple sclerosis. Lancet338, 1051–1055 (1991).
   Google Scholar
• Romine JS, Sipe JC, Koziol JA, Zyroff J, Beutler E. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc. Assoc. Am. Physicians111(1), 35–44 (1999).
   Google Scholar
• Skurkovich S, Boiko A, Believe I. Randomized study of antibodies to IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis. Mu/t. Scler. 7, 277–284 (2001).
   Google Scholar
• Martino G, Furlan R, Comi G, Adorini L. The ependymal route to the CNS: an emerging gene-therapy approach for MS. Trends Immunol. 22(9), 483–490 (2001).
   Google Scholar
• Barkhof F, van Waesberghe JH, Filippi M et al. T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-lb treatment. Brain 124\(Pt 7), 1396–1402 (2001).
   Google Scholar
• Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dahlke E Final analysis of the European multicenter trial on IFN-beta-lb in secondary-progressive MS. Neurology57(11), 1969–1975 (2001).
   PubMed Web of Science ®Google Scholar
• Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dahlke E European Study Group in Interferon beta-lb in Secondary-Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-lb in treatment of secondary progressive MS. Lancet 352, 1491–1497(1998).
   Google Scholar
• Lugaresi A, Caporale C, Farina D et al. Low-dose oral methotrexate treatment in chronic progressive multiple sclerosis Neurol. Sci. 22(2), 209–210 (2001).
   Google Scholar
• Mikaeloff Y, Moreau T, Debouverie M et al. Inteferon-B treatment in patients with childhood-onset multiple sclerosis. Pediatr. 139, 443–446 (2001).
   Google Scholar
• •Although follow-up is short and outcome criteria are unclear, this is the first report of a series of childhood MS treated with
   Google Scholar
• Takahashi I, Sawaishi Y, Takeda 0, Enoki M, Takada G. Childhood multiple sclerosis treated with plasmapheresis. Pediatr. Neurol. 17(1), 83–87 (1997).
   Google Scholar
• Boutin B, Esquivel E, Mayer M, Chaumet S, Ponsot G, Arthuis M. Multiple sclerosis in children: report of clincial and paraclinical features of 19 cases. Neuropediatrics 19,118–123 (1988).
   PubMed Web of Science ®Google Scholar
• Korinthenberg R. Chronic inflammatory demyelinating polyradiculoneuropathy in children and their response to treatment. Neuropediatrics 30,190–196 (1999).
   Google Scholar
• Waubant E, Hietpas J, Stewart T et al. Interferon beta-1a in children with multiple sclerosis is well-tolerated. Neuropediatrics 32(4), 211–213 (2001).
   Google Scholar
• Anlar B, Yalaz K, Köse G, Sayg S. Beta- interferon plus inosiplex in the treatment of subacute sclerosing panencephalitis. Child Neurol. 13(11), 557–559 (1998).
   Google Scholar
• Adams AB, Tyor WR, Holden KR. Interferon beta-lb and childhood multiple sclerosis. Pediatr. Neurol. 21(1), 81–83 (1999).
   Google Scholar
• Nevo Y, Topaloglu H. 88th ENMC international workshop: childhood chronic inflammatory demyelinating polyneuropathy (including revised diagnostic criteria), Naarden, The Netherlands, December 8–10, 2000. Neuromuscul. Disord 12(2), 195–200 (2002).
   Google Scholar